BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 12396664)

  • 1. Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease.
    Guillemin GJ; Brew BJ
    Redox Rep; 2002; 7(4):199-206. PubMed ID: 12396664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinolinic acid in the pathogenesis of Alzheimer's disease.
    Guillemin GJ; Williams KR; Smith DG; Smythe GA; Croitoru-Lamoury J; Brew BJ
    Adv Exp Med Biol; 2003; 527():167-76. PubMed ID: 15206729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus.
    Guillemin GJ; Brew BJ; Noonan CE; Takikawa O; Cullen KM
    Neuropathol Appl Neurobiol; 2005 Aug; 31(4):395-404. PubMed ID: 16008823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis.
    Guillemin GJ; Meininger V; Brew BJ
    Neurodegener Dis; 2005; 2(3-4):166-76. PubMed ID: 16909022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
    Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
    Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A beta 1-42 induces production of quinolinic acid by human macrophages and microglia.
    Guillemin GJ; Smythe GA; Veas LA; Takikawa O; Brew BJ
    Neuroreport; 2003 Dec; 14(18):2311-5. PubMed ID: 14663182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kynurenines, neurodegeneration and Alzheimer's disease.
    Kincses ZT; Toldi J; Vécsei L
    J Cell Mol Med; 2010 Aug; 14(8):2045-54. PubMed ID: 20629991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early modulation of the transcription factor Nrf2 in rodent striatal slices by quinolinic acid, a toxic metabolite of the kynurenine pathway.
    Colín-González AL; Luna-López A; Königsberg M; Ali SF; Pedraza-Chaverrí J; Santamaría A
    Neuroscience; 2014 Feb; 260():130-9. PubMed ID: 24361737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
    Tan L; Yu JT; Tan L
    J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer's disease.
    Chatterjee P; Zetterberg H; Goozee K; Lim CK; Jacobs KR; Ashton NJ; Hye A; Pedrini S; Sohrabi HR; Shah T; Asih PR; Dave P; Shen K; Taddei K; Lovejoy DB; Guillemin GJ; Blennow K; Martins RN
    J Neuroinflammation; 2019 Oct; 16(1):186. PubMed ID: 31601232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of quinolinic acid in the neuropathogenesis of amyotrophic lateral sclerosis.
    Lee JM; Tan V; Lovejoy D; Braidy N; Rowe DB; Brew BJ; Guillemin GJ
    Neuropharmacology; 2017 Jan; 112(Pt B):346-364. PubMed ID: 27265569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kynurenine and its metabolites in Alzheimer's disease patients.
    Gulaj E; Pawlak K; Bien B; Pawlak D
    Adv Med Sci; 2010; 55(2):204-11. PubMed ID: 20639188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kynurenine Pathway Metabolites as Biomarkers in Alzheimer's Disease.
    Liang Y; Xie S; He Y; Xu M; Qiao X; Zhu Y; Wu W
    Dis Markers; 2022; 2022():9484217. PubMed ID: 35096208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis.
    Guillemin GJ; Smith DG; Kerr SJ; Smythe GA; Kapoor V; Armati PJ; Brew BJ
    Redox Rep; 2000; 5(2-3):108-11. PubMed ID: 10939285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rollercoaster ride of kynurenines: steering the wheel towards neuroprotection in Alzheimer's disease.
    Sharma R; Razdan K; Bansal Y; Kuhad A
    Expert Opin Ther Targets; 2018 Oct; 22(10):849-867. PubMed ID: 30223691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection.
    Guillemin GJ; Kerr SJ; Smythe GA; Smith DG; Kapoor V; Armati PJ; Croitoru J; Brew BJ
    J Neurochem; 2001 Aug; 78(4):842-53. PubMed ID: 11520905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease.
    Ting KK; Brew BJ; Guillemin GJ
    J Neuroinflammation; 2009 Dec; 6():36. PubMed ID: 20003262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
    Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
    Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proinflammatory cytokine interferon-gamma increases induction of indoleamine 2,3-dioxygenase in monocytic cells primed with amyloid beta peptide 1-42: implications for the pathogenesis of Alzheimer's disease.
    Yamada A; Akimoto H; Kagawa S; Guillemin GJ; Takikawa O
    J Neurochem; 2009 Aug; 110(3):791-800. PubMed ID: 19457071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity.
    Varadarajan S; Yatin S; Aksenova M; Butterfield DA
    J Struct Biol; 2000 Jun; 130(2-3):184-208. PubMed ID: 10940225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.